Responses
Plenary sessions
Plenary 6
IGCS19-0765
33 Olaparib monotherapy versus (VS) chemotherapy for germline BRCA-mutated (GBRCAM) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (PTS): phase III solo3 trial
Compose a Response to This Article
Other responses
No responses have been published for this article.